ASCO: Bevacizumab Addition Works in Various Regimens

posted on Jun 07 by MedPage Today OB/Gyn in the Uncategorized category CHICAGO (MedPage Today) -- The addition of bevacizumab (Avastin) to most common chemotherapy regimens for metastatic breast cancer in women who have HER2-negative tumor biology appears to improve progression-free survival, researchers suggested here.